Grant-McAuley, Wendy
Laeyendecker, Oliver
Monaco, Daniel
Chen, Athena
Hudelson, Sarah E.
Klock, Ethan
Brookmeyer, Ron
Morrison, Douglas
Piwowar-Manning, Estelle
Morrison, Charles S.
Hayes, Richard
Ayles, Helen
Bock, Peter
Kosloff, Barry
Shanaube, Kwame
Mandla, Nomtha
van Deventer, Anneen
Ruczinski, Ingo
Kammers, Kai
Larman, H. Benjamin
Eshleman, Susan H.
Funding for this research was provided by:
U.S. President’s Emergency Plan for AIDS Relief
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
International Initiative for Impact Evaluation
Bill and Melinda Gates Foundation
National Institute of Allergy and Infectious Diseases (R01-AI095068)
National Institute on Drug Abuse
National Institute of Mental Health
Medical Research Council (MR/R010161/1)
National Institute of General Medical Sciences (R01-GM136724)
Article History
Received: 17 November 2021
Accepted: 7 November 2022
First Online: 11 November 2022
Declarations
:
: Written informed consent was obtained from participants prior to enrollment in the GS Study and HPTN 071 (PopART) Population Cohort. The GS Study was approved by ethical review boards at FHI 360, Case Western University, University of California, San Francisco and in Uganda and Zimbabwe. The HPTN 071 (PopART) trial was approved by the institutional review board and ethics committees at the London School of Hygiene and Tropical Medicine, the University of Zambia, and Stellenbosch University. The research reported in this manuscript was performed using stored samples and was approved by the Institutional Review Board of the Johns Hopkins University of Medicine. Research was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: H.B.L. is an inventor on an issued patent (US20160320406A) filed by Brigham and Women’s Hospital that covers the use of the VirScan technology, is a founder of ImmuneID, Portal Bioscience and Alchemab, and is an advisor to TScan Therapeutics. All other authors declare that they have no competing interests.